Spinal Dural Fistula

Comprehensive Clinical Guide: Spinal Dural Arteriovenous Fistula (SDAVF)

1. Introduction and Overview

A Spinal Dural Arteriovenous Fistula (SDAVF) is the most common form of spinal vascular malformation. It is a pathological connection between a radiculomeningeal artery and a coronal venous plexus, occurring typically at the level of the dural sleeve of the spinal nerve root.

Unlike high-flow arteriovenous malformations (AVMs), SDAVFs are low-flow, acquired lesions that lead to progressive venous hypertension. If left untreated, the resultant congestion of the spinal cord leads to ischemia, edema, and permanent neurological deficit. Because the symptoms often mimic common degenerative spinal conditions (such as lumbar disc herniation or spinal stenosis), SDAVFs are frequently misdiagnosed, leading to a critical delay in definitive intervention.

2. Etiology and Pathophysiology

The pathophysiology of SDAVF is characterized by "venous congestion" rather than direct mass effect or hemorrhage.

The Mechanism of Injury

1. The Fistula: A small feeding artery (usually from a radiculomeningeal branch) connects directly to a radicular vein within the dura mater.
2. Venous Hypertension: The high-pressure arterial blood enters the low-pressure venous system. This pressure is transmitted retrogradely into the coronal venous plexus of the spinal cord.
3. Impaired Drainage: The spinal cord’s intrinsic veins can no longer drain effectively against this increased pressure.
4. Chronic Ischemia: The resulting venous stasis causes chronic interstitial edema, impaired capillary perfusion, and eventually, myelomalacia (softening of the spinal cord).

Key Epidemiological Factors

• Demographics: Predominantly affects males (ratio of 4:1 to 5:1).
• Age: Typically presents in the 5th to 7th decades of life.
• Location: Most commonly located in the thoracolumbar region (T6–L2), corresponding to the levels with the most consistent radiculomeningeal supply.

3. Clinical Presentation and Grading

The clinical course of an SDAVF is insidious, often spanning 12 to 24 months before diagnosis.

Standard Presentation

• Progressive Myelopathy: Gradual onset of lower extremity weakness, sensory disturbances, and gait instability.
• Radicular Pain: Often mistaken for sciatica or radiculopathy.
• Autonomic Dysfunction: Urinary urgency, incontinence, or erectile dysfunction (often late-stage).
• "Claudication-like" Symptoms: Exacerbation of symptoms with physical activity or Valsalva maneuvers (due to increased venous pressure).

Clinical Staging (Aminoff-Logue Scale)

The Aminoff-Logue scale is widely utilized to quantify the severity of the neurological deficit:

4. Differential Diagnosis

Because SDAVFs are "great mimickers," clinicians must differentiate them from:
* Degenerative Spinal Stenosis: The most frequent misdiagnosis.
* Multiple Sclerosis: Especially when sensory deficits are patchy.
* Amyotrophic Lateral Sclerosis (ALS): Due to lower motor neuron signs.
* Spinal Cord Tumors: Intramedullary ependymomas or hemangioblastomas.
* Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

5. Diagnostic Investigations

A high index of suspicion is required. The diagnostic workflow follows a specific hierarchy.

MRI of the Spine (The Gold Standard Screening)

MRI findings are highly suggestive but not always conclusive:
* T2-Weighted Signal Hyperintensity: Intramedullary signal changes in the conus or thoracic cord.
* Flow Voids: Serpiginous, dilated vessels along the dorsal aspect of the spinal cord (the "pathognomonic sign").
* Contrast Enhancement: Often shows mild, diffuse enhancement of the spinal cord surface.

Digital Subtraction Angiography (DSA)

DSA remains the definitive diagnostic tool. It is essential for:
1. Confirming the presence of the fistula.
2. Identifying the exact anatomical level of the feeding artery.
3. Distinguishing SDAVF from other types of vascular malformations (e.g., Type II or III AVMs).

6. Treatment Modalities

The therapeutic goal is the complete obliteration of the fistula point to restore normal venous drainage.

• Microsurgical Ligation: The gold standard. A laminectomy is performed, the dura is opened, and the draining vein is coagulated and severed at the point where it exits the dura.
• Endovascular Embolization: Utilizing liquid embolic agents (e.g., Onyx or n-butyl cyanoacrylate). This is preferred in patients who are high-surgical risks or where the anatomy is favorable for liquid embolic penetration.

7. Risks and Contraindications

Surgical Risks

• CSF Leak: Risk of persistent dural leak post-operation.
• Infection: Standard risks associated with spinal instrumentation.
• Neurological Deterioration: Transient worsening of symptoms due to post-operative edema.

Contraindications

• Endovascular: Extreme tortuosity of the feeding artery preventing microcatheter access; high risk of non-target embolization (e.g., spinal cord supply).
• Surgical: Medical instability preventing general anesthesia; multi-level disease that cannot be accessed via a focal laminectomy.

8. Long-Term Prognosis

Prognosis is highly dependent on the pre-treatment neurological status.
* Improvement: Approximately 50–70% of patients experience significant improvement in symptoms post-treatment.
* Stabilization: Most patients achieve stabilization of their condition.
* Recovery Limitations: Once permanent myelomalacia (cord death) has occurred, neurological function is unlikely to return, even if the fistula is successfully obliterated. This underscores the necessity of early diagnosis.

9. Frequently Asked Questions (FAQ)

1. Is an SDAVF a type of cancer?
No, an SDAVF is a vascular malformation, not a tumor or a malignancy. It is a structural abnormality of blood vessels.

2. Why is it so frequently misdiagnosed?
Because the symptoms—leg weakness and back pain—are identical to common spinal stenosis or herniated discs, which are much more prevalent.

3. Does the fistula bleed?
Unlike brain AVMs, SDAVFs rarely bleed. The primary danger is venous congestion and cord ischemia.

4. What is the "pathognomonic" sign on an MRI?
The presence of "flow voids"—dark, tangled lines representing dilated, high-pressure veins on the surface of the spinal cord.

5. Can I live with an untreated SDAVF?
No. Untreated SDAVF causes progressive, permanent spinal cord damage that will eventually lead to significant disability.

6. Is surgery or embolization better?
Surgery is generally considered the gold standard with high cure rates. Embolization is used for specific anatomical cases or patients who cannot undergo surgery.

7. How fast does the condition progress?
It is typically a slow, progressive decline, but acute exacerbations can occur.

8. Can the fistula recur?
Recurrence is rare after complete surgical ligation, though follow-up imaging is recommended to ensure the fistula remains closed.

9. Will my symptoms go away immediately after surgery?
Usually, no. It takes months for the spinal cord to recover from the chronic swelling and ischemia.

10. Do I need special follow-up?
Yes. Periodic clinical neurological exams and follow-up MRI/MRA are necessary to monitor the cord signal and ensure no new vascular abnormalities develop.

10. Summary for Clinicians

The management of Spinal Dural Arteriovenous Fistulas requires a high level of vigilance. When a patient presents with progressive, unexplained myelopathy—especially in the setting of "sciatica" that does not respond to standard decompression—a high-quality MRI of the spine with contrast should be ordered immediately. If flow voids are detected, an urgent referral to a neuro-interventionalist or neurosurgeon specializing in spinal vascular disease is mandatory. Early intervention is the only factor that significantly correlates with a return to a high quality of life.